Clonal CD8+ and CD52- T cells are induced in responding B cell lymphoma patients treated with Campath-1H (anti-CD52). [electronic resource]
Producer: 19970228Description: 5-13 p. digitalISSN:- 0902-4441
- Adult
- Aged
- Alemtuzumab
- Antibodies, Monoclonal -- therapeutic use
- Antibodies, Monoclonal, Humanized
- Antibodies, Neoplasm -- therapeutic use
- Antigens, CD -- immunology
- Antigens, Neoplasm
- Antineoplastic Agents -- therapeutic use
- B-Lymphocytes -- immunology
- CD52 Antigen
- CD8-Positive T-Lymphocytes -- immunology
- Female
- Glycoproteins
- Humans
- Immunity, Cellular -- drug effects
- Leukemia, Lymphocytic, Chronic, B-Cell -- drug therapy
- Lymphoma, Non-Hodgkin -- drug therapy
- Male
- Middle Aged
- T-Lymphocyte Subsets -- immunology
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.